Industry and Company Overview - The medical consumables industry is undergoing significant changes with the recent announcement of the sixth batch of national high-value medical consumables centralized procurement, which took place on January 13, 2026. This procurement includes 12 types of medical consumables, with 496 products from 227 companies bidding, and 440 products from 202 companies selected [2][4]. - The procurement process emphasizes principles such as "stabilizing clinical use, ensuring quality, preventing internal competition, and avoiding collusion." This includes grouping products based on demand and supply capabilities to ensure that clinically recognized and capable products are selected [4]. Procurement Results and Implications - The results of the procurement are expected to be implemented by May 2026, allowing patients to access more reasonably priced and quality-assured products. The inclusion of drug-coated balloons and urological intervention consumables marks a significant step in addressing previously unaddressed areas in procurement [4]. - The procurement rules have been optimized to discourage traditional low-price competition strategies, pushing companies to focus on clinical value, supply stability, and innovation. This creates a more favorable environment for both large and small enterprises, particularly those with innovative products [4]. Investment Recommendations - The medical consumables industry, particularly high-end implantable devices such as orthopedic implants, cardiovascular intervention devices, and neurosurgical implants, is expected to benefit from policy support. The optimized procurement rules are likely to stabilize expectations and mitigate low-price competition [5]. - Companies with strong cost control, continuous innovation capabilities, and those that can achieve market share growth through domestic substitution are recommended for investment. Specific attention should be given to companies with product advantages in rehabilitation and chronic disease management [5].

Group 1: Market Overview - The global capital is increasingly focusing on the medical device distribution sector, with Medline Industries planning a potential IPO that could exceed a valuation of $50 billion, marking it as the largest IPO in the medical device industry by 2025 [1] - The Chinese medical device market is projected to reach a scale of 1.2 trillion yuan by 2024, with a significant acceleration towards intelligent supply chain solutions [2] - The traditional high-value consumables distribution in China remains fragmented and inefficient, with over 1.42 million companies involved, leading to long order processing times and inefficiencies [2] Group 2: Company Innovations - Jianfa Zhixin has recently listed on the ChiNext board, showcasing its innovative capabilities in reconstructing the supply chain value system [3] - The company has established a comprehensive medical supply chain hub, covering all provinces in China and serving over 3,300 medical institutions, with a focus on high-value interventional products [5] - Jianfa Zhixin's business model innovation includes a dual approach of direct sales and distribution, enhancing its service capabilities and collaboration with leading manufacturers [5] Group 3: Operational Efficiency - The company has implemented a Supply Chain Management (SPD) service model that addresses hospital management pain points, significantly improving operational efficiency [6][9] - Jianfa Zhixin has provided full-process operational services to 60 hospitals, managing over 10 billion yuan, with a notable recognition as a pilot unit for hospital logistics service standards [7] - The SPD model has demonstrated substantial improvements in resource allocation efficiency, reducing material requisition times and error rates in hospitals [9] Group 4: Digital Transformation - The company has built a robust digital supply chain management system, leveraging information technology and IoT to enhance operational efficiency and compliance [10] - Jianfa Zhixin's unique identification management technology addresses traditional coding issues, ensuring regulatory compliance and facilitating data flow from production to usage [10] Group 5: Market Potential and Capital Dynamics - The high-value medical device market in China has shown significant growth, with a compound annual growth rate of 15.79% from 2016 to 2023, providing a favorable environment for Jianfa Zhixin [12] - The capital market is experiencing a recovery, creating a conducive environment for Jianfa Zhixin's growth and valuation enhancement [15] - Analysts predict continued investment opportunities in the medical device sector, with a focus on undervalued stocks and supportive policies for innovation [18] Group 6: Strategic Outlook - The company's fundraising efforts will focus on upgrading information systems and enhancing centralized operations for medical consumables, reflecting a deep understanding of industry trends [19] - As management and business models continue to evolve, Jianfa Zhixin is expected to play a leading role in industry consolidation, with the capital market reassessing the value of leading companies in the medical device distribution sector [19]

Group 1 - The core market for domestic medical device companies has traditionally been first-tier cities, but there is a shift towards grassroots and overseas markets as of mid-2025 [1] - As of August 2023, 131 medical device companies are listed on A-shares, with nearly 100 companies mentioning sales activities in grassroots markets in their semi-annual reports, compared to only 4 companies in the same period in 2024 [1] - 90 companies reported overseas business income, with 67 experiencing year-on-year growth and 70 increasing the proportion of overseas income [1] Group 2 - The price drop due to centralized procurement has stimulated demand in grassroots markets, prompting companies to adjust their market strategies and seek new growth points [2] - For instance, Guichuang Tongqiao Medical Technology Co., Ltd. reported a revenue of 482 million yuan in the first half of 2024, a 31.7% increase year-on-year, largely due to increased sales from winning bids in centralized procurement [2] - The company also noted a 25.0% increase in sales revenue for neurovascular intervention products and a 46.2% increase for peripheral vascular intervention products in the first half of 2025 [2] Group 3 - The government has emphasized the need to expand and balance medical resources, pushing for quality medical resources to flow to county hospitals and grassroots healthcare [3] - The penetration rate of medical devices in second, third, and fourth-tier cities is expected to increase as residents' living standards and medical consumption rise [3] - The grassroots market is seen as a new profit growth point for medical device companies due to the large number of grassroots healthcare institutions and the currently low level of medical device configuration [3] Group 4 - Expanding into overseas markets is viewed as essential for the growth of medical device companies, with 33 out of 131 companies achieving double-digit revenue growth, driven significantly by overseas markets [4] - For example, Shanghai United Imaging Healthcare Co., Ltd. reported overseas revenue of 1.142 billion yuan in the first half of 2025, a 22.48% increase, with overseas orders continuing to grow rapidly [4] - Dongfulong Technology Group Co., Ltd. achieved overseas revenue of 805 million yuan, a 63.25% increase, surpassing domestic market growth for the first time [4] Group 5 - Guichuang Tongqiao's CEO expressed a desire to build capabilities overseas by integrating professional networks and enhancing the company's reputation through quality products [5] - The Chinese medical device industry possesses advantages in talent, clinical resources, cost, and supply chain, presenting opportunities to reshape the global market [5] - The industry may see more mergers and acquisitions as a means of expansion in the future [5]